2-amylbenzothiophene | 89969-72-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 2-amylbenzothiophene
• 英文别名: 2-pentylbenzo[b]thiophene；2-Pentyl-1-benzothiophene
• CAS: 89969-72-2
• 化学式: C₁₃H₁₆S
• 分子量: 204.336
• InChiKey: YMRWJTHTFNINDF-UHFFFAOYSA-N

物化性质

• 沸点：
  306.8±11.0 °C(Predicted)
• 密度：
  1.045±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-amylbenzothiophene 在 aluminum (III) chloride 、 乙醇 、 potassium hydroxide 作用下， 以 二氯甲烷 、 乙酸酐 为溶剂， 反应 10.5h， 生成 3-(2-methylbenzo[b]thiophen-3-yl)-4-(2-pentylbenzo[b]thiophen-3-yl)furan-2,5-dione
  参考文献：
  名称：

  On the use of diarylmaleimide derivatives in biological contexts: An investigation of the photochromic properties in aqueous solution

  摘要：

  A series of photochromic diarylmaleimide derivatives has been synthesized and studied with respect to the photochromic properties in aqueous solution. The main rationale is to investigate if these compounds could be used as photoswitchable units in biological contexts, motivated by the fact that the diarylmaleimide structural motif is identified in many pharmacophores. Thus, photoswitchable variants of this class of compounds could be very useful in the quest for photoactivatable drugs. The photoinduced cyclization reaction (colorization) is suppressed in solvents of high polarity, whereas the ring-opening reaction (decolorization) still occurs with high efficiency. The photochromically active anti-parallel conformer of the open form is more abundant in the asymmetrically substituted derivatives, which in turn favors the formation of the closed isomeric form. The rates of the thermal isomerization reactions have also been assessed, together with the resistance toward thermal degradation. Here it was observed that the maleimide derived compounds were not susceptible to the thermally driven reactions (hydrolysis and isomerization). (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.dyepig.2016.10.023
• 作为产物：
  描述：

  甲基苯基亚砜 在 2,6-二甲基吡啶 、 三氟甲磺酸 作用下， 以 乙腈 为溶剂， 反应 0.07h， 生成 2-amylbenzothiophene
  参考文献：
  名称：

  亚砜定向的芳香族和杂芳族化合物的无金属邻位炔丙基化

  摘要：

  芳族化合物和杂芳族化合物的亚砜导向，无金属邻位炔丙基化利用了炔丙基亲核分子的分子间传递给硫，然后分子内传递给碳。相对于炔丙基亲核试剂而言，操作简单的交叉偶联过程是通用的，区域特异性的，并且显示出邻炔丙基化产物相对于烯丙基化具有完全的选择性。仲炔丙基硅烷的使用可实现无金属邻位在芳族和杂芳族环与仲炔丙基中心之间偶联形成碳-碳键。亚砜导向基团的“安全捕获”性质在选择性，迭代的双交叉偶联过程中得到了说明。炔丙基化的产物是通用的中间体，它们已经很容易转化为取代的苯并噻吩。

  DOI：

  10.1002/chem.201406424

文献信息

• Cyclopenta[<i>b</i>]annulation of Heteroarenes by Organocatalytic γ′[C(sp³)−H] Functionalization of Ynones
  作者：Moluguri Raghu、Jagdeep Grover、S. S. V. Ramasastry

  DOI：10.1002/chem.201604562

  日期：2016.12.19

  to the designed ynones triggers γ′[C(sp3)−H] functionalization, leading to the formation of heteroaryl‐based ortho‐quinodimethane (oQDM) intermediates that undergo carbocyclization to provide cyclopentannulated heteroarenes in good yields and excellent stereoselectivities. Deuterium‐labeling experiments substantiated the proposed reaction mechanism as well as the speculated epimerization.

  对于环戊二烯并[一种新方法b通过金属和无定向基团的γ'[C（SP杂芳烃的]环3）-H]官能化和ynones的分子内加氢烷基化得到了发展。在史无前例的事件中，将有机膦亲核加成到设计的炔酮上会触发γ'[C（SP 3）-H]功能化，导致形成杂芳基邻喹啉二甲烷（oQDM）中间体，该中间体经过碳环化作用以提供环戊环杂芳烃具有良好的收率和出色的立体选择性。氘标记实验证实了拟议的反应机理以及推测的差向异构。
• Combinations of substituted azetidinones and CB1 antagonists
  申请人：Veltri P. Enrico

  公开号：US20060069080A1

  公开（公告）日：2006-03-30

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one selective CB 1 antagonist; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity, metabolic syndrome and lowering plasma levels of sterols or 5α-stanols.

  本发明提供了包括以下内容的组合物、治疗组合和方法：(a)至少一种选择性CB1拮抗剂；和(b)至少一种取代的氮杂环丁烷或取代的β-内酰胺甾醇吸收抑制剂，可用于治疗血管疾病、糖尿病、肥胖、代谢综合征以及降低血浆中的甾醇或5α-甾烷醇水平。
• 2-ARYLBENZOTHIOPHENE DERIVATIVES OR PHARCEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARCEUTICAL COMPOSITION FOR THE DIAGNOSIS OR TREATMENT OF DEGENERATIVE BRAIN DISEASE CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：Chi Dae Yoon

  公开号：US20100261727A1

  公开（公告）日：2010-10-14

  2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes: wherein R 1 -R 4 , V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.

  2-芳基苯并噻吩衍生物或其药用可接受盐，其制备方法，以及包含其作为活性成分的用于诊断或治疗退行性脑疾病的药物组合物。由于式1中的2-芳基苯并噻吩衍生物具有相对较高的β-淀粉样蛋白结合亲和力，因此当它们与放射性同位素标记时，它们可以作为诊断试剂用于通过非侵入性技术早期诊断阿尔茨海默病： 其中R1-R4，V，W，X，Y和Z如规范的详细描述中所定义。此外，当含有2-芳基苯并噻吩衍生物的药物组合物与低分子量β-淀粉样蛋白结合化合物结合时，最小化了恶性高分子量β-淀粉样蛋白沉积物的生成。因此，该药物组合物可用作治疗阿尔茨海默病等退行性脑疾病的治疗剂。
• Heterocyclic cannabinoid receptor antagonists
  申请人：Mayweg Alexander

  公开号：US20050250769A1

  公开（公告）日：2005-11-10

  The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.

  本发明涉及公式I的化合物及其药用盐。这些化合物可用于治疗和/或预防与CB1受体调节相关的疾病。
• Pyrazinecarboxamide derivatives as CB1 antagonists
  申请人：Hebeisen Paul

  公开号：US20070293509A1

  公开（公告）日：2007-12-20

  The present invention relates to compounds of the formula I: wherein R 1 to R 8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.

  本发明涉及以下式I的化合物： 其中R1至R8如描述和索赔中定义，并且其药学上可接受的盐。这些化合物对于治疗和/或预防与调节CB1受体相关的疾病，如肥胖症，是有用的。